Q3 EPS Forecast for Akebia Therapeutics Lifted by Analyst

Akebia Therapeutics, Inc. (NASDAQ:AKBA) – Investment analysts at HC Wainwright lifted their Q3 2025 earnings per share (EPS) estimates for Akebia Therapeutics in a research report issued on Thursday, October 30th. HC Wainwright analyst M. Caufield now anticipates that the biopharmaceutical company will post earnings per share of $0.01 for the quarter, up from their prior forecast of ($0.02). HC Wainwright currently has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Akebia Therapeutics’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Akebia Therapeutics’ Q4 2025 earnings at $0.01 EPS, FY2025 earnings at $0.04 EPS, FY2026 earnings at $0.31 EPS and FY2027 earnings at $0.26 EPS.

A number of other research firms have also commented on AKBA. Zacks Research lowered Akebia Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 13th. BTIG Research decreased their price objective on Akebia Therapeutics from $10.00 to $5.00 and set a “buy” rating on the stock in a research note on Wednesday, October 29th. Wall Street Zen raised Akebia Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Akebia Therapeutics in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $6.00.

Akebia Therapeutics Stock Down 4.1%

AKBA opened at $2.12 on Monday. The company has a quick ratio of 1.84, a current ratio of 1.98 and a debt-to-equity ratio of 1.61. The firm has a market cap of $562.11 million, a P/E ratio of -12.47 and a beta of 0.68. Akebia Therapeutics has a 52 week low of $1.52 and a 52 week high of $4.08. The business’s fifty day simple moving average is $2.87 and its 200 day simple moving average is $3.11.

Hedge Funds Weigh In On Akebia Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of AKBA. Abel Hall LLC acquired a new position in Akebia Therapeutics during the 2nd quarter valued at about $39,000. State of Alaska Department of Revenue acquired a new position in Akebia Therapeutics during the 3rd quarter valued at about $42,000. Wealth Enhancement Advisory Services LLC acquired a new position in Akebia Therapeutics during the 2nd quarter valued at about $59,000. Brevan Howard Capital Management LP acquired a new position in Akebia Therapeutics during the 2nd quarter valued at about $62,000. Finally, Unified Investment Management acquired a new position in Akebia Therapeutics during the 3rd quarter valued at about $49,000. Institutional investors own 33.92% of the company’s stock.

About Akebia Therapeutics

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.